Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O00754

UPID:
MA2B1_HUMAN

ALTERNATIVE NAMES:
Lysosomal acid alpha-mannosidase; Mannosidase alpha class 2B member 1; Mannosidase alpha-B

ALTERNATIVE UPACC:
O00754; G5E928; O15330; Q16680; Q93094; Q9BW13

BACKGROUND:
The enzyme Lysosomal alpha-mannosidase, with alternative names such as Mannosidase alpha-B, is essential for breaking down N-linked carbohydrates from glycoproteins. Its ability to cleave alpha-mannosidic linkages is critical for maintaining cellular health and proper glycoprotein degradation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Lysosomal alpha-mannosidase could open doors to potential therapeutic strategies for treating Mannosidosis, alpha B, lysosomal. This disease's link to the enzyme highlights the importance of targeted research in developing treatments for the associated severe and mild forms of the condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.